SG11201903348UA - Therapeutic compounds and methods of use thereof - Google Patents

Therapeutic compounds and methods of use thereof

Info

Publication number
SG11201903348UA
SG11201903348UA SG11201903348UA SG11201903348UA SG11201903348UA SG 11201903348U A SG11201903348U A SG 11201903348UA SG 11201903348U A SG11201903348U A SG 11201903348UA SG 11201903348U A SG11201903348U A SG 11201903348UA SG 11201903348U A SG11201903348U A SG 11201903348UA
Authority
SG
Singapore
Prior art keywords
international
way
south san
pct
san francisco
Prior art date
Application number
SG11201903348UA
Inventor
Daniel Sutherlin
Steven Mckerrall
Michael Scott Wilson
Kwong Wah Lai
Philippe Bergeron
Birong Zhang
Ramsay Beveridge
Jean-Philippe Leclerc
Alexandre Lemire
Liang Zhao
Claudio Sturino
Original Assignee
Genentech Inc
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Xenon Pharmaceuticals Inc filed Critical Genentech Inc
Publication of SG11201903348UA publication Critical patent/SG11201903348UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C07D261/16—Benzene-sulfonamido isoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 111111111111111111111010111 01111101011H01111110111100111111111111110111111111111 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\" WO 2018/072602 Al 26 April 2018 (26.04.2018) WIP0 I PCT (51) International Patent Classification: C07D 285/08 (2006.01) A61P 19/02 (2006.01) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. A61K 31/427 (2006.01) (84) Designated States (unless otherwise indicated, for every (21) International Application Number: PCT/CN2017/103499 kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (22) International Filing Date: 26 September 2017 (26.09.2017) UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (25) Filing Language: English MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (26) Publication Language: English TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (30) Priority Data: PCT/CN2016/102263 Published: 17 October 2016 (17.10.2016) CN — with international search report (Art. 21(3)) (71) Applicants: GENENTECH, INC. [US/US]; 1 DNA Way, South San Francisco, CA 94080-4990 (US). XENON PHARMACEUTICALS INC. [CA/CA]; 200-3650 Gilmore Way, Burnaby, British Columbia V5G 4W8 (CA). (72) Inventors; and _ (71) Applicants (for MN only): SUTHERLIN, Daniel [US/US]; 1 DNA Way, South San Francisco, CA = 94080-4990 (US). MCKERRALL, Steven [US/US]; 1 DNA Way, South San Francisco, CA 94080-4990 (US). = WILSON, Michael Scott [CA/CA]; 200-3650 Gilmore — = Way, Burnaby, British Columbia V5G 4W8 (CA). LAI, Kwong Wah [CN/CN]; 288 Fute Zhong Road, WaiGao- = = Qiao Free Trade Zone, Shanghai 200131 (CN). BERG- = ERON, Philippe [CA/US]; 1 DNA Way, South San Fran- cisco, CA 94080-4990 (US). ZHANG, Birong [US/US]; 1 — DNA Way, South San Francisco, CA 94080-4990 (US). = (74) Agent: WU, FENG & ZHANG; Sinosteel Plaza, 21st Floor A/D, 8 Haidian st., Haidian, Beijing 100080 (CN). = Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, = (81) = = = = — = MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, = 1-1 (54) ei Title: THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF 0 (57) : The invention provides a compound of formula I: or a pharmaceuti- D cally acceptable salt thereof, wherein the variables X, )( I -y -5 , R 1 , R 2 , — x3, R4, and Het IN IN R 2 0 p have the meaning as described herein, and compositions containing such compounds CZ 3 Het and methods for using ..Y.?, R1 s„ [1 such compoundsand compositions. 11 OO --.... r Y 1 0 (I) Ye y5 r., z R3 CZ ei X R 4 O
SG11201903348UA 2016-10-17 2017-09-26 Therapeutic compounds and methods of use thereof SG11201903348UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2016102263 2016-10-17
PCT/CN2017/103499 WO2018072602A1 (en) 2016-10-17 2017-09-26 Therapeutic compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11201903348UA true SG11201903348UA (en) 2019-05-30

Family

ID=62018232

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201903348UA SG11201903348UA (en) 2016-10-17 2017-09-26 Therapeutic compounds and methods of use thereof

Country Status (21)

Country Link
US (2) US10457654B2 (en)
EP (1) EP3526205A4 (en)
JP (1) JP2019532077A (en)
KR (1) KR20190078587A (en)
CN (1) CN110072855A (en)
AR (1) AR109964A1 (en)
AU (1) AU2017347549A1 (en)
BR (1) BR112019007763A2 (en)
CA (1) CA3039853A1 (en)
CL (1) CL2019001041A1 (en)
CO (1) CO2019004978A2 (en)
CR (1) CR20190236A (en)
IL (1) IL265955A (en)
MA (1) MA46546A (en)
MX (1) MX2019004232A (en)
PE (1) PE20190980A1 (en)
PH (1) PH12019500839A1 (en)
RU (1) RU2019114964A (en)
SG (1) SG11201903348UA (en)
TW (1) TW201821412A (en)
WO (1) WO2018072602A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10899732B2 (en) 2015-11-25 2021-01-26 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
US10793550B2 (en) 2017-03-24 2020-10-06 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
US11028075B2 (en) 2018-02-26 2021-06-08 Genentech, Inc. Therapeutic compounds and methods of use thereof
WO2019191702A1 (en) 2018-03-30 2019-10-03 F. Hoffmann-La Roche Ag Substituted hydro-pyrido-azines as sodium channel inhibitors
TW202003490A (en) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 Therapeutic compounds and methods of use thereof
WO2020248123A1 (en) * 2019-06-11 2020-12-17 Merck Sharp & Dohme Corp. Hydroxypyrrolidine-substituted arylsulfonamide compounds with selective activity in voltage-gated sodium channels
CN112745279A (en) * 2019-10-31 2021-05-04 杭州澳医保灵药业有限公司 Methazolamide and analogs thereof and application thereof in treatment of normal-pressure hydrocephalus
CN115784922B (en) * 2022-11-09 2024-03-29 苏州爱玛特生物科技有限公司 Preparation method of (2S) -2-amino-4- (cyclopropyl/cyclobutyl) butyric acid

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3705185A (en) 1969-04-14 1972-12-05 Minnesota Mining & Mfg N-aroyl sulfonamides
US4130566A (en) 1977-10-27 1978-12-19 Sumitomo Chemical Company, Limited Process for producing 5-carboxy-2-acetylthiophene
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (en) 1983-08-30 1985-04-24 Oreal COSMETIC OR PHARMACEUTICAL COMPOSITION IN AQUEOUS OR ANHYDROUS FORM WHOSE FATTY PHASE CONTAINS OLIGOMER POLYETHER AND NEW OLIGOMER POLYETHERS
GB8524157D0 (en) 1984-10-19 1985-11-06 Ici America Inc Heterocyclic amides
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
DK24089D0 (en) 1989-01-20 1989-01-20 Hans Bundgaard NOVEL PRODRUG DERIVATIVES OF BIOLOGICALLY ACTIVE AGENTS CONTAINING HYDROXYL GROUPS OR NH-ACIDIC GROUPS
GB8911854D0 (en) 1989-05-23 1989-07-12 Ici Plc Heterocyclic compounds
NZ258747A (en) 1992-11-23 1997-02-24 Hoechst Marion Roussel Inc Sub 3-heterocyclyalkylamino benzisoxazole derivatives; medicaments
PT729463E (en) 1993-11-19 2002-10-31 Parke Davis & Co 5,6-DIHIDROPIRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS
US5573653A (en) 1994-07-11 1996-11-12 Sandoz Ltd. Electrochemical process for thiocyanating aminobenzene compounds
DK0779281T3 (en) 1994-08-30 2004-03-08 Sankyo Co isoxazoles
US5753653A (en) 1995-12-08 1998-05-19 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
GB9828442D0 (en) 1998-12-24 1999-02-17 Karobio Ab Novel thyroid receptor ligands and method II
US6608105B2 (en) 2000-12-18 2003-08-19 Meiji Dairies Corporation TNF-α production inhibitor comprising kavalactone as an active ingredient
KR100789567B1 (en) 2001-11-06 2007-12-28 동화약품공업주식회사 A 3-amido-1,2-benzoisoxazole derivatives, process for preparation, and use thereof
DE10201550A1 (en) 2002-01-17 2003-07-31 Merck Patent Gmbh Phenoxy piperidines
EP1529049B1 (en) 2002-08-08 2009-11-18 Memory Pharmaceuticals Corporation Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors
PE20040801A1 (en) 2002-12-12 2004-11-25 Hoffmann La Roche PYRAZINE AND PYRIDINE 5-SUBSTITUTED DERIVATIVES AS GLUCOKINASE ACTIVATORS
KR20060009846A (en) 2003-04-15 2006-02-01 화이자 인코포레이티드 Alpha substituted carboxylic acid as ppar modulators
ZA200601942B (en) 2003-08-08 2007-05-30 Vertex Pharma Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
PE20050358A1 (en) * 2003-08-08 2005-05-16 Vertex Pharma COMPOSITIONS REFERRED TO INHIBITORS OF VOLTAGE REGULATED ION CHANNELS
ATE448222T1 (en) 2003-10-03 2009-11-15 Portola Pharm Inc 2,4-DIOXO-3-CHINAZOLINYLARYLSULFONYL UREAS
US7081539B2 (en) 2004-03-25 2006-07-25 Dainippon Sumitomo Pharma Co., Ltd. One-pot process for the preparation of 1,2-benzisoxazole-3-methanesulfonamide
CA2574971A1 (en) 2004-07-30 2006-02-09 Merck & Co., Inc. Indanone potentiators of metabotropic glutamate receptors
DE602005020313D1 (en) 2004-08-12 2010-05-12 Amgen Inc Bis-aryl SULPHONAMIDES
CA2581638A1 (en) 2004-09-29 2006-04-13 Portola Pharmaceuticals, Inc. Substituted 2h-1,3-benzoxazin-4(3h)-ones
JP2008189549A (en) 2005-05-12 2008-08-21 Astellas Pharma Inc Carboxylic acid derivative or its salt
DE102005038947A1 (en) 2005-05-18 2006-11-30 Grünenthal GmbH Substituted benzo [d] isoxazol-3-yl-amine compounds and their use in medicaments
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7915410B2 (en) 2005-09-09 2011-03-29 Bristol-Myers Squibb Company Acyclic IKur inhibitors
RU2008119412A (en) 2005-10-19 2009-11-27 Ф.Хоффманн-Ля Рош Аг (Ch) N-Phenyl-Phenylacetamide Non-Nucleoside Inhibitors of Reverse Transcriptase
CA2630234A1 (en) 2005-11-23 2007-05-31 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
AR058296A1 (en) 2005-12-09 2008-01-30 Kalypsys Inc INHIBITORS OF HISTONA DEACETILASE AND PHARMACEUTICAL COMPOSITION
MX2008013194A (en) 2006-04-11 2008-12-01 Vertex Pharma Compositions useful as inhibitors of voltage-gated sodium channels.
ATE542818T1 (en) 2006-10-11 2012-02-15 Amgen Inc IMIDAZO AND TRIAZOLOPYRIDINE COMPOUNDS AND METHOD OF USE THEREOF
EP2108019A2 (en) 2007-01-30 2009-10-14 Biogen Idec MA, Inc. 1-h-pyrazolo[3,4b]pyrimidine derivatives and their use as modulators of mitotic kinases
CA2677493A1 (en) 2007-02-05 2008-08-14 Xenon Pharmaceuticals Inc. Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions
ES2340640T3 (en) 2007-03-23 2010-06-07 Icagen, Inc. ION CHANNEL INHIBITORS.
NZ581309A (en) 2007-05-25 2012-02-24 Vertex Pharma Ion channel modulators and methods of use
JPWO2008149965A1 (en) 2007-06-07 2010-08-26 アステラス製薬株式会社 Pyridone compounds
US20090012103A1 (en) 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
TW200911766A (en) 2007-07-13 2009-03-16 Astrazeneca Ab New compounds
CA2693588C (en) * 2007-07-13 2015-11-17 Icagen, Inc. Sodium channel inhibitors
US20110092703A1 (en) 2007-08-10 2011-04-21 Nippon Chemiphar Co., Ltd. P2x4 receptor antagonist
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
JP5304785B2 (en) 2008-06-23 2013-10-02 アステラス製薬株式会社 Sulfonamide compound or salt thereof
WO2010022055A2 (en) 2008-08-20 2010-02-25 Amgen Inc. Inhibitors of voltage-gated sodium channels
WO2010079443A1 (en) 2009-01-12 2010-07-15 Pfizer Limited Sulfonamide derivatives
ES2642586T3 (en) 2009-07-27 2017-11-16 Gilead Sciences, Inc. Condensed heterocyclic compounds as ion channel modulators
US8809380B2 (en) 2009-08-04 2014-08-19 Raqualia Pharma Inc. Picolinamide derivatives as TTX-S blockers
ES2532866T3 (en) 2009-09-25 2015-04-01 Astellas Pharma Inc. Substituted amide compound
WO2011059042A1 (en) 2009-11-12 2011-05-19 武田薬品工業株式会社 Aromatic ring compound
US8471034B2 (en) 2009-11-18 2013-06-25 Concert Pharmaceuticals, Inc. Niacin prodrugs and deuterated versions thereof
TW201139406A (en) 2010-01-14 2011-11-16 Glaxo Group Ltd Voltage-gated sodium channel blockers
AU2011215833B2 (en) 2010-02-12 2015-07-09 Nivalis Therapeutics, Inc. Novel S-nitrosoglutathione reductase inhibitors
WO2011153588A1 (en) 2010-06-10 2011-12-15 Biota Scientific Management Pty Ltd Viral polymerase inhibitors
US20120004714A1 (en) 2010-06-30 2012-01-05 Ryan Kleve Lead having coil electrode with preferential bending region
WO2012004664A2 (en) 2010-07-07 2012-01-12 Purdue Pharma L.P. Analogs of sodium channel peptide toxin
CA2804593C (en) 2010-07-09 2015-11-24 Pfizer Limited Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors
US9096558B2 (en) 2010-07-09 2015-08-04 Pfizer Limited N-sulfonylbenzamide compounds
US9145407B2 (en) 2010-07-09 2015-09-29 Pfizer Limited Sulfonamide compounds
US9096500B2 (en) 2010-07-12 2015-08-04 Pfizer Limited Acyl sulfonamide compounds
US9102621B2 (en) 2010-07-12 2015-08-11 Pfizer Limited Acyl sulfonamide compounds
EP2593427B1 (en) 2010-07-12 2014-12-24 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
CA2801032A1 (en) 2010-07-12 2012-01-19 Pfizer Limited N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
US8772343B2 (en) 2010-07-12 2014-07-08 Pfizer Limited Chemical compounds
WO2012007836A1 (en) 2010-07-16 2012-01-19 Purdue Pharma .Lp. Pyridine compounds as sodium channel blockers
NZ608116A (en) 2010-09-13 2014-05-30 Novartis Ag Triazine-oxadiazoles
WO2012039657A1 (en) 2010-09-22 2012-03-29 Astrazeneca Ab Novel chromane compound for the treatment of pain disorders
JP2014500303A (en) 2010-12-22 2014-01-09 パーデュー、ファーマ、リミテッド、パートナーシップ Substituted pyridines as sodium channel blockers
WO2012095781A1 (en) 2011-01-13 2012-07-19 Pfizer Limited Indazole derivatives as sodium channel inhibitors
RU2634900C2 (en) 2011-02-02 2017-11-08 Вертекс Фармасьютикалз Инкорпорейтед Spirocyclic pyrrolopyrazine(piperidine)amides as ionic channels modulators
BR112013024502B1 (en) 2011-03-25 2021-09-08 Glaxosmithkline Intellectual Property (No.2) Limited CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS INCLUDING SUCH COMPOUNDS
MX2014001851A (en) 2011-08-17 2014-10-24 Amgen Inc Heteroaryl sodium channel inhibitors.
EP2766018A4 (en) 2011-10-13 2015-02-25 Univ Case Western Reserve Rxr agonists compounds and methods
KR20140095067A (en) 2011-10-28 2014-07-31 머크 샤프 앤드 돔 코포레이션 Benzoxazolinone compounds with selective activity in voltage-gated sodium channels
MX2014005304A (en) 2011-10-31 2015-03-20 Xenon Pharmaceuticals Inc Biaryl ether sulfonamides and their use as therapeutic agents.
RU2014121984A (en) 2011-10-31 2015-12-10 Ксенон Фармасьютикалз Инк. BENZENESULPHONAMIDE COMPOUNDS AND THEIR APPLICATION AS A THERAPEUTIC MEDICINES
US9133131B2 (en) 2011-11-15 2015-09-15 Purdue Pharma L.P. Pyrimidine diol amides as sodium channel blockers
WO2013086229A1 (en) 2011-12-07 2013-06-13 Amgen Inc. Bicyclic aryl and heteroaryl sodium channel inhibitors
EP2791108B1 (en) 2011-12-15 2016-07-27 Pfizer Limited Sulfonamide derivatives
EP2800740A1 (en) 2012-01-04 2014-11-12 Pfizer Limited N-aminosulfonyl benzamides
JP2015083542A (en) 2012-02-08 2015-04-30 大日本住友製薬株式会社 Three substituted proline derivative
US8889741B2 (en) * 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives
WO2013122897A1 (en) * 2012-02-13 2013-08-22 Amgen Inc. Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
US9051311B2 (en) 2012-03-09 2015-06-09 Amgen Inc. Sulfamide sodium channel inhibitors
WO2013146969A1 (en) 2012-03-29 2013-10-03 第一三共株式会社 Novel disubstituted cyclohexane derivative
AU2013266398A1 (en) 2012-05-22 2015-01-22 Genentech, Inc. N-substituted benzamides and their use in the treatment of pain
MX2015000164A (en) 2012-07-06 2015-08-12 Genentech Inc N-substituted benzamides and methods of use thereof.
JP6220786B2 (en) 2012-07-19 2017-10-25 大日本住友製薬株式会社 1- (Cycloalkylcarbonyl) proline derivative
BR112015008987A2 (en) 2012-10-26 2017-07-04 Merck Sharp & Dohme compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, and use of a pharmaceutical composition
AU2013334663A1 (en) 2012-10-26 2015-05-07 Merck Sharp & Dohme Corp. Benzoxazolinone compounds with selective activity in voltage-gated sodium channels
EP2935257B1 (en) 2012-12-20 2018-02-07 Purdue Pharma LP Cyclic sulfonamides as sodium channel blockers
BR112015018289A2 (en) 2013-01-31 2017-07-18 Vertex Pharma pyridone amides as sodium channel modulators
US20140296266A1 (en) 2013-03-01 2014-10-02 Gilead Sciences, Inc. Therapeutic compounds
CA2905613C (en) * 2013-03-14 2017-11-28 Daiichi Sankyo Company, Limited Drug for respiratory diseases
RU2015143906A (en) 2013-03-14 2017-04-18 Дженентек, Инк. SUBSTITUTED TRIAZOLOPYRIDINES AND WAYS OF THEIR APPLICATION
CN105188694B (en) 2013-03-15 2018-07-31 卓莫赛尔公司 Sodium channel modulators for treating pain
RU2015143834A (en) 2013-03-15 2017-04-24 Дженентек, Инк. SUBSTITUTED BENZOXAZOLE AND METHODS OF USE
WO2015051043A1 (en) 2013-10-01 2015-04-09 Amgen Inc. Biaryl acyl-sulfonamide compounds as sodium channel inhibitors
EA201691085A1 (en) * 2013-11-27 2017-02-28 Дженентек, Инк. SUBSTITUTED BENZAMIDES AND METHODS OF THEIR APPLICATION
WO2015077905A1 (en) 2013-11-29 2015-06-04 Merck Sharp & Dohme Corp. Bicycloamine-substituted-n-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels
CR20170591A (en) 2015-05-22 2018-05-07 Genentech Inc BENZAMIDS REPLACED AND METHODS TO USE THEM
MY194015A (en) * 2015-11-13 2022-11-08 Daewoong Pharmaceutical Co Ltd Sodium channel blocker
KR20180096683A (en) 2015-12-18 2018-08-29 머크 샤프 앤드 돔 코포레이션 Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels
EP3390374B1 (en) 2015-12-18 2020-08-26 Merck Sharp & Dohme Corp. Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels
US10442778B2 (en) 2016-03-22 2019-10-15 Merck Sharp & Dohme Corp. N1-phenylpropane-1,2-diamine compounds with selective activity in voltage-gated sodium channels
US10668067B2 (en) 2016-07-20 2020-06-02 Amgen Inc. Pyridine sulfonamides

Also Published As

Publication number Publication date
PE20190980A1 (en) 2019-07-09
MA46546A (en) 2021-05-05
AU2017347549A1 (en) 2019-05-02
JP2019532077A (en) 2019-11-07
WO2018072602A1 (en) 2018-04-26
BR112019007763A2 (en) 2019-07-02
CA3039853A1 (en) 2018-04-26
CL2019001041A1 (en) 2019-06-21
EP3526205A1 (en) 2019-08-21
TW201821412A (en) 2018-06-16
CO2019004978A2 (en) 2019-07-31
US20200115354A1 (en) 2020-04-16
KR20190078587A (en) 2019-07-04
CR20190236A (en) 2019-09-09
AR109964A1 (en) 2019-02-06
US20180105504A1 (en) 2018-04-19
IL265955A (en) 2019-05-30
CN110072855A (en) 2019-07-30
PH12019500839A1 (en) 2019-06-24
RU2019114964A (en) 2020-11-17
RU2019114964A3 (en) 2021-01-29
EP3526205A4 (en) 2020-05-27
MX2019004232A (en) 2019-08-01
US10457654B2 (en) 2019-10-29

Similar Documents

Publication Publication Date Title
SG11201903348UA (en) Therapeutic compounds and methods of use thereof
SG11201908820VA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201907544VA (en) Jak inhibitors containing a 4-membered heterocyclic amide
SG11201810834WA (en) Hepatitis b antiviral agents
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201805645QA (en) Lsd1 inhibitors
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201810600WA (en) Fxr (nr1h4) modulating compounds
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201804152RA (en) Heterocyclic compounds as immunomodulators
SG11201804373VA (en) Compositions and methods for immunooncology
SG11201807708SA (en) Estrogen receptor modulators
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201909011PA (en) Niraparib compositions
SG11201809751XA (en) Egfr inhibitor compounds
SG11201908786VA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201908465QA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201806267QA (en) Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose
SG11201907434RA (en) Compositions and methods for immunooncology
SG11201808270PA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201906163TA (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds